S&P 500 Futures stretch recovery from one week low as vaccine expectations gain momentum


  • S&P 500 Futures rise 10 points, or 0.30%, while extending pullback from the lowest since November 13.
  • Vaccine hopes rise as Regeneron’s anti-body treatment gets FDA’s go, Pfizer up for getting UK’s green light this week.
  • US President-elect Biden starts forming the team before reaching the White House.
  • UK, France and Australia are among the nations likely to ease the covid-led activity restrictions.

S&P 500 Futures probe the intraday high of 3,565.88, up 0.31% on a day, amid the Asian session on Monday. The risk barometer recently picked up bids as optimism concerning the coronavirus (COVID-19) vaccine/treatments joined expected easing in the lockdown measures from the key economies.

Having heard about the 95% success rate of Pfizer’s covid vaccine and US President Donald Trump’s recovery after taking the Regeneron’s antibody treatment, news that the US Food and Drug Administration (FDA) approved the COVID-19 therapy added to the market’s optimism. Also favoring the risks could be the hints that Pfizer will get the UK’s regulatory approval by the end of this week.

Further, easing of coronavirus-led activity restrictions in the UK, France and Australia are additional positives for the risks.

It should also be noted that US President-elect Joe Biden’s activity to form the team before the current President Donald Trump accepts his defeat also favors the risk-on mood. Bloomberg recently mentioned that the Democratic member is up for announcing Antony Blinken as secretary of State while naming Jake Sullivan as a National Security Adviser.

On the contrary, a sustained rise in the US hospitalizations and the tussle between the US Federal Reserve and Treasury Department, over $500 billion’s recall by Treasury Secretary Steve Manuchin, also probes the optimists. Additionally, Brexit uncertainties and doubts over the US COVID-19 stimulus also raise worries for the market players.

That said, traders can keep their eyes on the preliminary readings of November’s activity numbers from Markit for fresh impulse. However, risk catalysts can keep the driver’s seat.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Feed news

Latest Forex News


Latest Forex News

Editors’ Picks

EUR/USD: Corrective pullback fades below previous support, 200-SMA

EUR/USD remains on the back foot, receding taking rounds to 1.2120-25, amid a sluggish Asian session trading on Wednesday. Sellers to keep reins as unless prices cross three-week-old resistance line. Easing bullish bias of MACD adds to the downside signals.

EUR/USD News

GBP/USD: Bears in control, cling to multi-day support near 1.4080

The GBP/USD pair started the session on Wednesday on a lower note. The pair recovered from the low of 1.4034 on Tuesday to close near the 1.4080 mark, where it waivers now. Momentum oscillator hints at downside momentum.

GBP/USD News

EUR/USD: Corrective pullback fades below previous support, 200-SMA

EUR/USD remains on the back foot, receding taking rounds to 1.2120-25, amid a sluggish Asian session trading on Wednesday. Sellers to keep reins as unless prices cross three-week-old resistance line. Easing bullish bias of MACD adds to the downside signals.

EUR/USD News

Cardano may drop 30% as hard-core believers vanish

Cardano price resolved a symmetrical triangle to the downside on June 11 and has wedged calmly higher, discovering resistance at the declining 50 twelve-hour SMA. 2018 high is critical support on weakness and is the only significant obstacle between ADA and a test of the May 19 low.

Read more

Stocks ease ahead of Fed, pricing pressures grow, retail sales drop, mixed dollar

US stocks are slightly softer heading into the FOMC as the stimulus boost wanes, inflation fears grow, and the economic recovery shows signs of softening.  A wrath of US economic data delivered a somewhat mixed picture for Fed policy.

Read more

Forex MAJORS

Cryptocurrencies

Signatures